# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HC Wainwright & Co. analyst Yi Chen reiterates Clearside Biomedical (NASDAQ:CLSD) with a Buy and maintains $5 price target.
Chardan Capital analyst Daniil Gataulin initiates coverage on Clearside Biomedical (NASDAQ:CLSD) with a Buy rating and annou...
HC Wainwright & Co. analyst Yi Chen reiterates Clearside Biomedical (NASDAQ:CLSD) with a Buy and maintains $5 price target.
Needham analyst Serge Belanger reiterates Clearside Biomedical (NASDAQ:CLSD) with a Buy and maintains $4 price target.
Clearside Biomedical (NASDAQ:CLSD) reported quarterly losses of $(0.10) per share which beat the analyst consensus estimate of ...
HC Wainwright & Co. analyst Yi Chen reiterates Clearside Biomedical (NASDAQ:CLSD) with a Buy and maintains $5 price target.
Needham analyst Serge Belanger reiterates Clearside Biomedical (NASDAQ:CLSD) with a Buy and maintains $4 price target.